$JBSS

JBSS reported Q4 2026 net sales up 4.2% to $280.4M, but net income fell to $8.4M from $13.5M YoY. Challenges included higher costs and manufacturing inefficiencies. Priorities for 2027 include restoring snack volume, expanding the Thar portfolio, and managing cost volatility. The company expects $300M in potential new growth.

John B. Sanfilippo & Son's (JBSS) fair value estimate was reduced by 8% to $100.00, citing margin concerns despite stronger revenue expectations. Analysts at Freedom Broker upgraded the stock to Buy in 2026, highlighting pricing and valuation support, but also noted margin pressure. Revenue growth assumptions increased to 2.41%, while net profit margin expectations dropped to 5.26%.

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Fourth Quarter and Full Year Results Fourth Quarter Net Sales Increased 4.2%; Sales Volume Increased 1.4% Elgin, IL, August 19, 2026 -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced fi

SANFILIPPO JOHN B & SON INC (JBSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0000880117 SANFILIPPO JOHN B & SON INC 0000880117 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earlies

John B. Sanfilippo & Son, Inc. has issued a voluntary recall for various trail mix and nut products, including some sold at Target, due to potential Salmonella contamination from a dry milk powder used as seasoning. Although no Salmonella has been detected in the seasoning and no illnesses have been reported, the recall is a precautionary measure. Consumers are advised to dispose of the products or return them for a refund, and aware of Salmonella symptoms, which can be severe for vulnerable populations.

SANFILIPPO JOHN B&SON (JBSS) reported strong Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted earnings of $1.43 per share against an estimate of $1.18, and revenue reached $281,780,000, exceeding the $266,041,500 estimate. This news follows a period of mixed institutional investor activity and a recent "Buy" rating from BWS Financial.

John B. Sanfilippo & Son (NASDAQ:JBSS) announced its quarterly earnings, reporting an EPS of $1.43, exceeding analyst estimates of $1.16 by $0.27. The company's revenue reached $281.78 million, surpassing the consensus of $260.83 million. Additionally, John B. Sanfilippo declared a special dividend of $1.50 per share payable on May 21st, with the stock currently holding a "Hold" rating from analysts and an average price target of $109.00.

BWS Financial has reaffirmed its "Buy" rating for John B. Sanfilippo & Son (NASDAQ:JBSS), setting a price target of $109, which suggests a potential upside of 36% from its current price. This reiteration comes despite mixed analyst views, with the company currently holding a "Hold" consensus rating according to MarketBeat. John B. Sanfilippo & Son recently surpassed Q4 EPS estimates, reporting $1.53 against an expected $1.36, and institutional investors own a significant portion of its shares.

Short interest for John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) decreased by 21.1% in December to 153,925 shares. Analysts currently have a "Hold" rating on the stock with a consensus price target of $109.00. The company recently reported strong quarterly earnings, beating estimates, and paid a special dividend.

ETR, CNP, JBSS and UVV stand out as consumer sentiment sinks, with low beta, rising earnings estimates and a steady dividend drawing defensive investors.